Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alendronate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    51 result(s) found for: Alendronate. Displaying page 3 of 3.
    « Previous 1  2  3 
    EudraCT Number: 2021-002476-39 Sponsor Protocol Number: RLX0121 Start Date*: 2021-07-29
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: Prospective study to evaluate the effects of Raloxifene therapy on SARS-CoV-2 immunity after COVID-19 vaccination
    Medical condition: The study will be conducted in non-oncological female patients older than 50 years who have received the first dose of a COVID vaccination, or who have received the full vaccination within 8 weeks...
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001865-28 Sponsor Protocol Number: 08/H0802/9 Start Date*: 2008-05-30
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guys and St Thomas NHS Foundation Trust
    Full Title: The Relationship between Osteoporosis and Aortic Calcification in Postmenopausal Women
    Medical condition: Osteoporosis; Aortic Calcification
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10054208 Aortic calcification PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005712-22 Sponsor Protocol Number: 01-2020 Start Date*: 2021-07-08
    Sponsor Name:Gedeon Richter Ibérica
    Full Title: Prospective, randomized, multicenter study to compare the efficacy at 52 weeks (1 year) of biosimilar teriparatide and alendronate in the prevention of new morphometric vertebral fractures and / or...
    Medical condition: Osteoporosis in postmenopausal women at increased risk of fracture.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10031290 Osteoporotic fracture PT
    Population Age: Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006015-72 Sponsor Protocol Number: CR9108963 Start Date*: 2007-08-10
    Sponsor Name:GlaxoSmithKline Research and Development Ltd.
    Full Title: Study CR9108963: A 12-month, randomized, double blind, parallel-group, placebo and active-controlled dose-range finding study of the efficacy and safety of SB-751689 in post-menopausal women with o...
    Medical condition: Post-menopausal Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) DK (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000635-94 Sponsor Protocol Number: DEM100175 Start Date*: 2006-05-11
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Phase II, randomized, double-blind, parallel group study to examine bone quality and bone mineral density changes following treatment with SB-462795 (40mg, 80mg, 120mg or 160mg), alendronate or p...
    Medical condition: Osteoporosis
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002780-82 Sponsor Protocol Number: 63513 Start Date*: 2005-07-20
    Sponsor Name:Richter Gedeon Rt
    Full Title: Alendronat (Sedron 70 mg) hatékonyságának és biztonságosságának nyílt, multicentrikus, fázis IV vizsgálata osteoporosisban szenvedő veseköves férfibetegekben
    Medical condition: osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    8.0 10031282 PT
    Population Age: Adults Gender: Male
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-000988-28 Sponsor Protocol Number: 19403 Start Date*: 2011-08-16
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Fractures and Bisphosphonates: A double-blind, randomised controlled trial on the effect of alendronic acid on healing and clinical outcomes of wrist fractures
    Medical condition: Fracture healing
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10017076 Fracture PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005991-28 Sponsor Protocol Number: 20060326 Start Date*: 2009-06-26
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women with Low Bone Mineral Density
    Medical condition: Postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) ES (Completed) DK (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002948-24 Sponsor Protocol Number: 20080289 Start Date*: 2013-04-08
    Sponsor Name:Amgen, Inc.
    Full Title: An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment with AMG 785 in Postmenopausal Women with Osteoporosis Previously Treated with Bisphosphonate Therapy
    Medical condition: Post Menopausal Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DK (Completed) ES (Completed) GB (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-007456-34 Sponsor Protocol Number: 3100N0-2213-WW Start Date*: 2009-09-04
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: Estudio de fase 2, multicéntrico, aleatorizado, controlado con producto activo, de grupos paralelos, búsqueda de dosis y de la seguridad de la proteína morfogenética de hueso humano recombinante 2 ...
    Medical condition: Sujetos con disminución de la densidad mineral ósea (DMO) en riesgo de fractura de cadera
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031282 Osteoporosis LLT
    9.1 10031282 Osteoporosis PT
    Population Age: Elderly Gender: Female
    Trial protocol: ES (Completed) BE (Completed) PL (Completed) FI (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-001153-17 Sponsor Protocol Number: 262 Start Date*: 2008-06-16
    Sponsor Name:MSD
    Full Title: Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combinat...
    Medical condition: Postmenopausal women with osteoporosis at increased risk of falls.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) LT (Completed) GB (Completed) BE (Completed) LV (Completed) FR (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 18 06:28:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA